An announcement from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Limited has issued 100,000 fully paid shares under its Employee Incentive Plan, in compliance with the Corporations Act. This move reflects the company’s ongoing efforts to incentivize its workforce and align employee interests with corporate goals, potentially impacting its operational dynamics and market positioning.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their product portfolio includes the CelGro™ platform of collagen medical devices for tissue reconstruction and healing, Striate+™ for dental applications, Remplir™ for peripheral nerve reconstruction, and SmrtGraft™ for tendon repair. The company is also advancing autologous cell therapies aimed at regenerating damaged tendon and cartilage tissue.
YTD Price Performance: -4.43%
Average Trading Volume: 1,799,878
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$313.2M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.